St. Clair Advisors LLC Takes Position in Gilead Sciences, Inc. (NASDAQ:GILD)

St. Clair Advisors LLC purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the fourth quarter, Holdings Channel reports. The fund purchased 5,219 shares of the biopharmaceutical company’s stock, valued at approximately $482,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Triglav Skladi D.O.O. purchased a new stake in Gilead Sciences during the 4th quarter worth approximately $1,478,000. Tidal Investments LLC increased its stake in Gilead Sciences by 36.9% during the 4th quarter. Tidal Investments LLC now owns 152,591 shares of the biopharmaceutical company’s stock worth $14,095,000 after buying an additional 41,127 shares during the period. State of Wyoming purchased a new stake in Gilead Sciences during the 4th quarter worth approximately $590,000. Strategic Global Advisors LLC increased its stake in Gilead Sciences by 4.2% during the 4th quarter. Strategic Global Advisors LLC now owns 37,285 shares of the biopharmaceutical company’s stock worth $3,444,000 after buying an additional 1,490 shares during the period. Finally, Tema Etfs LLC purchased a new stake in Gilead Sciences during the 4th quarter worth approximately $2,849,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have commented on GILD. Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and boosted their price target for the stock from $80.00 to $120.00 in a report on Tuesday, February 18th. JPMorgan Chase & Co. boosted their price target on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an “overweight” rating in a report on Thursday, March 27th. The Goldman Sachs Group boosted their price target on shares of Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a report on Wednesday, February 12th. Cantor Fitzgerald initiated coverage on shares of Gilead Sciences in a report on Tuesday, April 22nd. They set an “overweight” rating and a $125.00 price target for the company. Finally, Wells Fargo & Company upped their target price on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th. Nine research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $110.55.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $104.09, for a total value of $260,225.00. Following the sale, the chief financial officer now directly owns 169,061 shares of the company’s stock, valued at approximately $17,597,559.49. This represents a 1.46% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 25,429 shares of company stock worth $2,894,445 in the last 90 days. 0.27% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Up 2.2%

Shares of Gilead Sciences stock opened at $102.50 on Monday. The company has a market cap of $127.50 billion, a P/E ratio of 277.03, a PEG ratio of 0.71 and a beta of 0.26. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $119.96. The firm has a fifty day moving average of $105.75 and a two-hundred day moving average of $99.84.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.04. The business had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The business’s revenue was down .3% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.32) EPS. On average, analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be issued a $0.79 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 3.08%. Gilead Sciences’s dividend payout ratio is presently 66.53%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.